Camzyos (Mavacamten)

• Cardiac Concerns: In the presence of intercurrent illness, thoughtful consideration should be given to the temporary interruption of CAMZYOS in patients with heart failure.
• Potential for Drug Interactions and Impact on Cardiac Health: Patients should be informed about the potential for drug interactions, including those with over-the-counter medications, which may lead to heart failure or diminished effectiveness.
• Risk of Embryo-Fetal Toxicity: CAMZYOS carries the potential to cause harm to the fetus. Women of reproductive potential should be advised to employ effective contraception until four months after the final dose. It is recommended to use contraception unaffected by CYP450 enzyme induction or consider nonhormonal contraceptive methods.

If you are considering the import of Camzyos (Mavacamten) to India, please be aware that Camzyos can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical professional.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Camzyos will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Camzyos in India:

Camzyos is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Camzyos can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Camzyos (prescription medicines) to locations both within India and worldwide while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Indian Pharma Network is proficient in sourcing Camzyos (Mavacamten)  from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedited prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.

Is Camzyos approved by the FDA?

In April 2022, the FDA approved Camzyos to treat adults with symptomatic New York Heart Association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms. 

What is the FDA indication for Mavacamten?

CAMZYOS (Mavacamten) is used to treat adults with symptomatic NYHA class II-III obstructive HCM to improve functional capacity and symptoms.

How fast does Camzyos work?

Camzyos starts working right after you take your first dose. However, it may take several weeks for the symptoms of your condition to start easing. In clinical trials, many people with obstructive HCM had fewer symptoms by 30 weeks after starting treatment with the drug.

Is Camzyos safe to use?

Camzyos may cause serious side effects such as heart failure. Get medical help right away if one experience new or worsening symptoms, like shortness of breath and chest pain.